心力衰竭中的炎症:JACC前沿综述
该综述阐述炎症参与心力衰竭(HF)发病与进展的机制,讨论传统与新型炎症生物标志物,并总结抗炎治疗临床试验的最新证据。尽管炎症指标与HF严重程度及预后相关,但抗炎治疗试验大多未成功;作者提出未来需精准定义HF表型并深入理解特定炎症介质的作用,以实现靶向抗炎治疗改善预后。
要点
- 炎症指标与HF严重程度和预后相关,但抗炎治疗临床试验大多未成功。
- 精准定义HF综合征内的特定表型是尚未实现的目标。
- 深入理解特定炎症介质的作用可能使靶向抗炎治疗改善预后。
核心结论
- 炎症参与HF发病与进展,但抗炎治疗试验大多未成功,靶向精准表型的抗炎治疗是尚未实现的目标。
研究设计与样本
- JACC前沿综述,描述炎症与HF的机制联系、讨论传统与新型炎症生物标志物并总结抗炎治疗临床试验最新证据。
主要发现
- 众多研究验证了炎症指标与HF严重程度和预后的关联。
- 抗炎治疗临床试验大多未成功。
临床怎么用
- 期待通过精准定义HF表型并更好理解特定炎症介质作用,使靶向抗炎治疗改善炎症病理生物学驱动HF患者的预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It has long been observed that heart failure (HF) is associated with measures of systemic inflammation. In recent years, there have been significant advancements in our understanding of how inflammation contributes to the pathogenesis and progression of HF. However, although numerous studies have validated the association between measures of inflammation and HF severity and prognosis, clinical trials of anti-inflammatory therapies have proven mostly unsuccessful. On this backdrop emerges the yet unmet goal of targeting precise phenotypes within the syndrome of HF; if such precise definitions can be realized, and with better understanding of the roles played by specific inflammatory mediators, the expectation is that targeted anti-inflammatory therapies may improve prognosis in patients whose HF is driven by inflammatory pathobiology. Here, the authors describe mechanistic links between inflammation and HF, discuss traditional and novel inflammatory biomarkers, and summarize the latest evidence from clinical trials of anti-inflammatory therapies.
引用
- Murphy SP, Kakkar R, McCarthy CP, et al. Inflammation in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020. PMID: 32192660. doi:10.1016/j.jacc.2020.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。